

new imaging techniques, essentially represented by 18-FDG PET-scan, also seems to modify our practice in DLBCL treatment. Other approaches are based on the introduction of new therapeutic compounds, targeting the tumor cells itself or its micro-environment: anti-angiogenic compounds, proteasome or mTOR inhibitors, IMiDs. Some of these drugs may benefit to selected patients subgroups, characterized by particular biological features. Current standards, options and investigational therapeutic approaches in various subgroups of DLBCL patients will also be discussed.

14

Recent progress in the treatment for T-cell malignancies

P.L. Zinzani*. *Institute of Hematology and Medical Oncology "L. e A. Seràgnoli", University of Bologna, Bologna, Italy*

New therapeutic approaches and the incorporation of novel agents into these therapeutic regimens are necessary to improve the outcome for peripheral T-cell lymphoma (PTCL) patients.

Nucleoside analogs: Nucleoside analogs are chemotherapeutic agents that primarily inhibit DNA replication and repair. There are three subgroups of nucleoside analogs: pyrimidine nucleoside analogs, purine nucleoside analogs, and the metabolic enzyme inhibitors. Gemcitabine is the most effective pyrimidine nucleoside analog in PTCL. It has been active both as a single agent and in combination with alemtuzumab and bortezomib. The purine nucleoside analogs include cladribine, fludarabine, clofarabine, and nelarabine. Both cladribine and fludarabine have shown efficacy in PTCL, and clofarabine and nelarabine are currently in several clinical trials in T-cell lymphoma.

Monoclonal antibodies: The addition of the anti-CD20 monoclonal antibody (MAb) rituximab to chemotherapy regimens like CHOP has significantly improved treatment outcomes in B-cell lymphoma. As such, several monoclonal antibodies are currently being tested in PTCL, including alemtuzumab, iratumumab, sipilizumab, and zanolimumab.

Conjugates: Denileukin diftitox is an antineoplastic agent that combines interleukin-2 with diphtheria toxin, and it has been approved by the US Food and Drug Administration (FDA) for use in cutaneous T-cell lymphomas (CTCL). In PTCL patients, the combination of denileukin diftitox and CHOP produced enhanced response rates (ORR of 86.5%) when compared to historical data using CHOP alone.

Proteasome inhibitors: Bortezomib, a proteasome inhibitor, has been well tolerated and active as a single agent in relapsed or refractory CTCL patients. It has also been used with positive results in combinations with gemcitabine ± doxorubicin, and recent evidence shows that bortezomib may synergize with pralatrexate in T-cell lymphoma (see folate analog section below).

Histone deacetylase inhibitors: Histone deacetylase (HDAC) inhibitors are potent inducers of histone acetylation, which results in the expression of tumor suppressor genes that had been previously silenced by deacetylation. This gene expression leads to cell cycle arrest and apoptosis. There are a number of HDAC inhibitors being used or studied in T-cell lymphoma, including vorinostat, romidepsin (also known as depsipeptide), panobinostat, and belinostat. Vorinostat and romidepsin have shown single-agent activity in CTCL, and vorinostat was approved by the FDA in 2006 for the treatment of cutaneous T-cell lymphoma (CTCL). There is limited data on the activity of HDAC inhibitors in PTCL, and further study is needed for HDAC inhibitors, both as single agents and in combination with other types of agents, such as retinoids, antiangiogenic agents, proteasome inhibitors, chemotherapeutic agents, and demethylating agents.

15

Mantle cell lymphoma: Current standards and new approaches

M. Dreyling*. *University Hospital Großhadern, Department of Medicine III, Munich, Germany*

Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin's lymphomas characterized by the chromosomal translocation t(11;14)(q13;q32) and nuclear cyclin D1 overexpression in the vast majority of cases.

Most patients present with advanced stage disease, often with extranodal dissemination, and pursue an aggressive clinical course in the majority of cases [1]. With the exception of allogeneic hematopoietic stem cell transplantation, current treatment approaches are non-curative and the corresponding survival curves are characterized by a delayed, but continuous decline and a median survival of 4–6 years [2,3]. However, a subset of 15 % long-term survivors have been identified with a rather indolent clinical course even after conventional treatment strategies only [4].

Recently, a prognostic score has been established implementing age and performance status of the patient, LDH and leukocyte count [5]. Moreover, the strong prognostic impact of minimal response has been increasingly recognized [6].

At least concerning initial response rates, improvement has been achieved by the successful introduction of monoclonal antibodies with a CHOP-like or other conventional chemotherapies [7,8]. In younger patients, dose-intensified approaches including autologous stem cell transplantation (ASCT) strategies has further improved progression-free survival rates [3,9,10].

Emerging strategies including proteasome inhibitors [11], IMiDs [12], mTOR inhibitors [13] and others are based on the dysregulated control of cell cycle machinery and impaired apoptotic pathways. Monotherapy of these compounds achieve efficacy comparable to conventional chemotherapy in relapsed MCL, and combination strategies are currently being investigated in numerous trials, however their introduction into clinical practice and current treatment algorithms remains a challenge [14].

Full protocol versions of the *European MCL Network* are available under: www.european-mcl.net.

Reference(s)

- [1] Dreyling M, Hiddemann W: Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book Hematology 2009: 542–554.
- [2] Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, Reiser M, Forstpointner R, Metzner B, Peter N, Wörmann B, Trümper L, Pfreundschuh M, Einsele H, Hiddemann W, Unterhalt M, Dreyling M. Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma. *J Clin Oncol* 2009 Feb 1;27(4):511–8.
- [3] Tam CS, Bassett R, Ledesma C, et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. *Blood* 2009; 113: 4144–4152.
- [4] Martin P, Chadburn A, Christos P, et al: outcome of deferred initial therapy in mantle-cell lymphoma. *J Clin Oncol* 2009; 27: 1209–1213.
- [5] Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wörmann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M. A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. *Blood* 2008 Jan 15;111(2):558–65.
- [6] Pott C, Hoster E, Delfau-Larue MH, et al: Molecular remission is an independent predictor of clinical